Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EH03
|
| gptkbp:brand |
gptkb:Tukysa
|
| gptkbp:CASNumber |
1315326-29-0
|
| gptkbp:chemicalFormula |
C26H24N8O2
|
| gptkbp:combinationTherapy |
gptkb:capecitabine
gptkb:trastuzumab |
| gptkbp:developedBy |
gptkb:Seattle_Genetics
|
| gptkbp:genericName |
gptkb:tucatinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tukysa
|
| gptkbp:indication |
metastatic breast cancer
locally advanced breast cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
HER2 tyrosine kinase inhibitor
|
| gptkbp:molecularWeight |
480.52 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:palmar-plantar_erythrodysesthesia
nausea diarrhea fatigue hepatotoxicity |
| gptkbp:usedFor |
gptkb:cancer
gptkb:HER2-positive_breast_cancer |
| gptkbp:bfsParent |
gptkb:Seagen
|
| gptkbp:bfsLayer |
5
|